The Volumetric Response to Bronchodilators in Stable Chronic Obstructive Pulmonary Disease

REFERENCES

• Miller M R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten C P, Gustafsson P, Jensen R, Johnson D C, MacIntyre N, McKay R, Navajas D, Pedersen O F, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force Standardisation of spirometry. Eur Respir J 2005; 26: 319–338
   PubMed Web of Science ®Google Scholar
• Nisar M, Harris J E, Pearson M G, Calverley P MA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 555–559
   PubMed Web of Science ®Google Scholar
• Hay J G, Stone P, Carter J, Church S, Eyre-Brook A, Pearson M G, Woodcock A A, Calverley P M. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 659–664
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Lam M, Webb K A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542–549
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society. 2005, URL: http://www.ersnet.org. Standards for the diagnosis and treatment of people with COPD. Accessed 24 July 2007
   Google Scholar
• Global Initiative for Chronic Lung Disease (GOLD). 2006, URL: http://www.gold.com. GOLD Workshop Report, 2006 update. Accessed 24 July 2007
   Google Scholar
• National Institute for Clinical Effectiveness. Chronic Obstructive Pulmonary Disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. 2004, Accessed 24 July 2007 URL: http://www.nice.org.uk.
   Google Scholar
• Ramsdell J W, Tisi G M. Determination of bronchodilation in the clinical pulmonary function laboratory. Chest 1979; 76: 622–662
   PubMed Web of Science ®Google Scholar
• Girard W M, Light R W. Should the FVC be considered in evaluating response to bronchodilator. Chest 1983; 84: 87–89
   PubMed Web of Science ®Google Scholar
• Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, van de Woestijne K P, Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88: 1989–1995
   PubMed Web of Science ®Google Scholar
• van Noord J A, Bantje T A, Eland M E, Korducki L, Cornelissen P J. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289–294
   Google Scholar
• American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107–1136
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique, 1995 update. Am J Respir Crit Care Med 1995; 152: 2185–2198
   PubMed Web of Science ®Google Scholar
• Tweeddale P M, Alexander F, McHardy G JR. Short-term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42: 487–490
   PubMed Web of Science ®Google Scholar
• Calverley P M, Koulouris N G. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25: 186–99
   PubMed Web of Science ®Google Scholar
• Hansen E F, Phanareth K, Laursen L C, KokJensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267–1271
   PubMed Web of Science ®Google Scholar
• Walker P P, Mitchell P, Diamantea F, Warburton C J, Davies L. Effect of Primary Care Spirometry on the Diagnosis and Management of COPD. Eur Respir J 2006; 28: 945–952
   PubMed Web of Science ®Google Scholar
• Belman M J, Botnick W C, Shin J W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967–975
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Brusasco V. Lung hyperinflation and flow limitation in chronic airway obstruction. Eur Respir J 1997; 10: 543–549
   PubMed Web of Science ®Google Scholar
• Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive disease patients. Eur Respir J 1998; 12: 799–804
   PubMed Web of Science ®Google Scholar
• Boni E, Corda L, Franchini D, Chiroli P, Damiani G P, Pini L, Grassi V, Tantucci C. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528–532
   PubMed Web of Science ®Google Scholar
• Stevenson N J, Walker P P, Costello R W, Calverley P M. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1510–1516
   PubMed Web of Science ®Google Scholar
• Hadcroft J, Calverley P MA. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713–720
   PubMed Web of Science ®Google Scholar
• Aliverti A, Rodger K, Dellaca R L, Stevenson N, Lo Mauro A, Pedotti A, Calverley P M. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005; 60: 916–924
   PubMed Web of Science ®Google Scholar
• Calverley P M, Burge P S, Spencer S, Anderson J A, Jones P W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659–664
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Wright E C. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814–819
   PubMed Web of Science ®Google Scholar